|
Volumn 355, Issue 6320, 2017, Pages 29-30
|
Reprogramming to resist: Prostate cancer cells alter identity to resist therapy
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ABIRATERONE;
ANDROSTANOLONE;
DNA METHYLTRANSFERASE 1;
ENZALUTAMIDE;
MESSENGER RNA;
PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;
PROTEIN P53;
RETINOBLASTOMA BINDING PROTEIN 1;
SYNAPTOPHYSIN;
TESTOSTERONE;
TRANSCRIPTION FACTOR E2F;
TRANSCRIPTION FACTOR EZH2;
TRANSCRIPTION FACTOR SOX2;
CANCER;
CELLS AND CELL COMPONENTS;
DISEASE TREATMENT;
GENE EXPRESSION;
GENETIC ANALYSIS;
GENETIC MARKER;
TESTOSTERONE;
ADENOCARCINOMA IN SITU;
ANDROGEN SYNTHESIS;
CANCER CELL;
CANCER GROWTH;
CANCER RESISTANCE;
CANCER THERAPY;
CASTRATION RESISTANT PROSTATE CANCER;
CELL PLASTICITY;
DNA METHYLATION;
GENE EXPRESSION;
GENE SILENCING;
HUMAN;
INDUCED PLURIPOTENT STEM CELL;
LNCAP CELL LINE;
NEUROENDOCRINE DISEASE;
NONHUMAN;
NUCLEAR REPROGRAMMING;
PHENOTYPIC VARIATION;
PRIORITY JOURNAL;
PROSTATE CANCER;
REVIEW;
RNA SEQUENCE;
TUMOR RECURRENCE;
CELLULAR REPROGRAMMING;
HUMANS;
INDUCED PLURIPOTENT STEM CELLS;
|
EID: 85009266752
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.aam5355 Document Type: Review |
Times cited : (13)
|
References (13)
|